NASDAQ:ADTX Aditxt (ADTX) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free ADTX Stock Alerts $3.12 -0.25 (-7.42%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$3.04▼$3.3750-Day Range$3.12▼$6.1252-Week Range$3.04▼$76.40Volume61,397 shsAverage Volume149,826 shsMarket Capitalization$748,800.00P/E RatioN/ADividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aditxt alerts: Email Address Aditxt MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,855.1% Upside$61.00 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($80.82) to ($51.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.23 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAditxt has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.00, Aditxt has a forecasted upside of 1,855.1% from its current price of $3.12.Amount of Analyst CoverageAditxt has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.88% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently decreased by 53.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAditxt does not currently pay a dividend.Dividend GrowthAditxt does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADTX. Previous Next 3.5 News and Social Media Coverage News SentimentAditxt has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aditxt this week, compared to 2 articles on an average week.Search Interest12 people have searched for ADTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aditxt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.23% of the stock of Aditxt is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aditxt are expected to grow in the coming year, from ($80.82) to ($51.28) per share.Price to Book Value per Share RatioAditxt has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Aditxt Stock (NASDAQ:ADTX)Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Read More ADTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADTX Stock News HeadlinesMarch 13, 2024 | americanbankingnews.comShort Interest in Aditxt, Inc. (NASDAQ:ADTX) Declines By 54.0%March 7, 2024 | prnewswire.comFor Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended PregnancyMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 10, 2024 | markets.businessinsider.comAditxt CEO Provides Short-Term Loan to Bolster StabilityFebruary 10, 2024 | msn.comAditxt, Inc. Enters New Financial Obligation Impacting InvestorsFebruary 3, 2024 | msn.comAditxt Announces Merger Agreement with Evofem BiosciencesJanuary 30, 2024 | msn.comAditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devicesJanuary 30, 2024 | finance.yahoo.comAditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology ApplicationsMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.January 18, 2024 | msn.comAditxt files to sell 3.79M shares for holdersJanuary 14, 2024 | benzinga.comAditxt Stock (NASDAQ:ADTX), Short Interest ReportJanuary 13, 2024 | benzinga.comAditxt Stock (NASDAQ:ADTX) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 MillionJanuary 5, 2024 | finance.yahoo.comAditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq RulesJanuary 3, 2024 | bizjournals.comRichmond's Aditxt reaches deal to acquire maker of PhexxiJanuary 3, 2024 | marketwatch.comAditxt Shares Drop 24% After Pricing of Private PlacementJanuary 2, 2024 | finance.yahoo.comAditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity RequirementDecember 29, 2023 | finance.yahoo.comAditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq RulesDecember 29, 2023 | benzinga.comWhat's Going On With Aditxt Stock?December 12, 2023 | msn.comWhy Is Life Sciences-Focused Aditxt Stock Trading Higher Today?December 12, 2023 | markets.businessinsider.comCrude Oil Down 4%; Aditxt Shares Spike HigherDecember 12, 2023 | tmcnet.comADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to ShareholdersDecember 1, 2023 | nasdaq.comAditxt, Inc. Common Stock (ADTX)November 30, 2023 | finance.yahoo.comAditxt, Inc. (ADTX) Stock Price, News, Quote & History - Yahoo FinanceNovember 30, 2023 | msn.comWhat's Going On With Aditxt Inc Stock?November 30, 2023 | msn.comWhy Is Aditxt (ADTX) Stock Up 70% Today?November 16, 2023 | benzinga.comThis Life Sciences Company Aims To "Make Promising Innovations Possible Together"See More Headlines Receive ADTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today3/19/2024Next Earnings (Estimated)3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADTX CUSIPN/A CIK1726711 Webwww.aditxt.com Phone650-870-1200FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$61.00 Low Stock Price Target$61.00 Potential Upside/Downside+1,855.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,650,000.00 Net Margins-3,946.13% Pretax Margin-3,946.13% Return on Equity-777.58% Return on Assets-349.33% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.23 Sales & Book Value Annual Sales$930,000.00 Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$50.04 per share Price / Book0.06Miscellaneous Outstanding Shares240,000Free Float236,000Market Cap$748,800.00 OptionableNo Data Beta1.28 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Amro A. Albanna (Age 54)Co-Founder, Chairman & CEO Comp: $472.12kDr. Shahrokh Shabahang D.D.S. (Age 61)M.S., Ph.D., Co-Founder, Chief Innovation Officer, Secretary & Director Comp: $323.5kMr. Thomas J. Farley CPA (Age 51)Chief Financial Officer Comp: $357.89kMs. Corinne D. Pankovcin CPA (Age 58)M.B.A., Chief Commercialization Officer Comp: $366.77kMs. Rowena Albanna (Age 58)Chief Operating Officer Ms. Jennifer LeeDirector of Human ResourcesDr. Dolly B. Tyan Ph.D.Senior Vice President of Clinical Development TransplantationMr. Ge Chen M.D.M.S., Senior Vice President of Preclinical Research & DiscoveryMore ExecutivesKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCNovaBay PharmaceuticalsNYSE:NBYNeptune Wellness SolutionsNASDAQ:NEPTEvofem BiosciencesNASDAQ:EVFMDMK PharmaceuticalsNASDAQ:DMKView All CompetitorsInsidersParibas Securities Corp BnpSold 20,800 sharesTotal: $691,184.00 ($33.23/share)View All Insider Transactions ADTX Stock Analysis - Frequently Asked Questions Should I buy or sell Aditxt stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADTX shares. View ADTX analyst ratings or view top-rated stocks. What is Aditxt's stock price target for 2024? 1 brokerages have issued 1 year price objectives for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they expect the company's share price to reach $61.00 in the next twelve months. This suggests a possible upside of 1,855.1% from the stock's current price. View analysts price targets for ADTX or view top-rated stocks among Wall Street analysts. How have ADTX shares performed in 2024? Aditxt's stock was trading at $6.63 on January 1st, 2024. Since then, ADTX stock has decreased by 52.9% and is now trading at $3.12. View the best growth stocks for 2024 here. Are investors shorting Aditxt? Aditxt saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 17,300 shares, a decrease of 54.0% from the February 14th total of 37,600 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.9% of the shares of the stock are short sold. View Aditxt's Short Interest. When is Aditxt's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our ADTX earnings forecast. How were Aditxt's earnings last quarter? Aditxt, Inc. (NASDAQ:ADTX) released its quarterly earnings data on Wednesday, August, 11th. The company reported ($840.00) earnings per share for the quarter, missing the consensus estimate of ($100.00) by $740.00. Aditxt had a negative trailing twelve-month return on equity of 777.58% and a negative net margin of 3,946.13%. When did Aditxt's stock split? Aditxt's stock reverse split on Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Aditxt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Block (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS). Who are Aditxt's major shareholders? Aditxt's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amro A Albanna, Corinne Pankovcin, Paribas Securities Corp Bnp, Shahrokh Shabahang and Thomas J Farley. View institutional ownership trends. How do I buy shares of Aditxt? Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADTX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.